177 results about "Dermal fibroblast" patented technology

The invention is directed compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic preparations to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue.

The present invention relates to a composition for treating skin comprising an acylated short chain bioactive peptide and fulvic acid, and optionally colloidal gold. The invention further relates to a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The invention further relates to a method of treating wrinkled skin by topically administering the composition to an individual in need of such treatment.

The present invention provides a three-dimensional tissue equivalent for in-vivo and in-vitro uses. The three dimensional tissue equivalent of the present invention is a non-contractile cellular sheet cultured over a porous scaffold using a macromass culturing technique, for example where the cellular sheet is entirely on one side of a porous sponge. In one embodiment, the present invention provides a dermal wound dressing that comprises a high density cellular sheet of dermal fibroblast cells.

Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.

This invention relates to compositions comprising an ethanolamine derivative and an organic salt of zinc and/or magnesium. It further relates to the use of such compositions in topical formulations, in particular in anti-aging formulations. The invention further relates to the use of such compositions to promote human dermal fibroblasts growth and to combat the effects of skin aging.

The invention provides a method for constructing tissue engineering skin. In the method, human epidermal stem cells and hypodermal fibroblasts are taken as seed cells, and a homologous acellular dermal matrix modified by a human placental type IV collagen is taken as a stent, so that active dual-layer engineering skin is compounded and constructed by using a gas-liquid interface separate culture method. The tissue engineering skin constructed by using the method is closer to the structure of natural skin; and as proved by histomorphology, the tissue engineering skin has an epidermal and hypodermal double-layer structure, wherein the hypodermal collagen stent has a complete structure, an epidermal layer is provided with a plurality of layers of cells of different differentiation degrees, and the morphological requirement of the tissue engineering skin is met.

The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.

The invention is directed to compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic preparations to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue.

An autologous topical formulation containing conditioned medium obtained from culture of autologous fibroblasts has been developed. Unlike other topical formulations, it is autologous since it is derived solely from cells obtained by the person who is to use the formulation. This avoids any possible reaction with proteins derived from the cells. Preferred formulations include gels, creams, lotions, and ointments. The topical formulations of conditioned medium obtained by culturing autologous dermal fibroblasts are topically administered to individuals for the prevention and treatment of scarring, reduction in signs of aging, and improvement in quality of skin.

The present inventors revealed the following for the first time in the world:

• 1) a large amount of bone marrow-derived cells are mobilized to grafted skin;
• 2) the mobilized bone marrow-derived cells are differentiated into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in the grafted skin, and the mobilized bone marrow derived cells include bone marrow-derived mesenchymal stem cells;
• 3) the factors which mobilize bone marrow-derived mesenchymal stem cells from peripheral blood to the grafted skin are HMGB1, HMGB2, and HMGB3 released from the necrosed tissue of recipient skin;
• 4) purified HMGB1, HMGB2, and HMGB3 promote the migration of mesenchymal stem cells isolated and cultured from bone marrow;
• 5) activators containing HMGB1 which allows the migration of bone marrow mesenchymal stem cells can be conveniently purified from several organ extracts including skin, brain, and heart;
• 6) activators which allow the migration of bone marrow mesenchymal stem cells can be conveniently extracted from cultured cells; and
• 7) a heparin-column purified fraction of skin extract mobilizes a large amount of bone marrow-derived cells in case of brain injury.

The present invention includes peptides, compositions as well as their use for the prevention or treatment of various age related or pathological conditions of skin or other tissues including skin wrinkles, wounds, different types of fibrosis and methods of reconstructing different tissues such as techniques used in regenerative medicine. The invention further includes peptide mimetics and methods of use including interfering with transcriptional complexes characteristic of fibroblasts of aged skin and stimulating synthesis of structural components of extracellular matrix.

A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90α or the middle domain plus the charged sequence of hsp90α. The composition is topically applied to skin wounds, covering the outer surface of the wound. The heat shock protein acts by promoting migration of both human epidermal keratinocyte and dermal fibroblasts to the wound in order to close, heal, and remodel the wound.

The invention provides a hair follicle reconstruction method based on hair follicle stem cells and fibroblast. The method provided by the invention comprises the steps of: (1) culturing and amplifying the hair follicle stem cells; (2) culturing and amplifying the fibroblast; and (3) mixing the amplified hair follicle stem cells and the amplified fibroblast, and inoculating a mixture to a position to be subjected to hair follicle reconstruction. Because the hair follicle stem cells can be passed massively in a long term and the dermis fibroblast is convenient to obtain, the method provided by the invention has very strong actual application prospect and scientific and research potential, is an important method for reconstructing skin and hair follicles in treating large-area skin injury (such burns, scalds and the like), and is also a first choice to testify the hair follicle stem cells in scientific researches.

The invention provides the use of silica for cosmetic and/or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that silica exhibits a multi-faceted biological effect useful in the cosmetic and/or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that silica induces markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induces collagen expression in dermal fibroblasts and inhibits UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6).

The invention provides compound cockroach glucosides A to C and a drug composition thereof and their application in preparation of pharmaceuticals and health-care products for treating ulcers and burns and scalds. Ulcers and burns are fairly common, and American cockroaches clinically used for various ulcers and burns have a good effect. Three dihydrogen isocoumarin glucosides are separated and identified and are named as the cockroach glucosides A, B and C, and all the cockroach glucosides can promote dermal fibroblast collagen secretion of human and improve the treatment effect on the collagen secretion lack diseases, such as all kinds of ulcers, burns and scalds.

An artificial collagen gel skin is prepared from ox tendon collagen dispersing liquid 80 portions, DMEM culture liquid 10, glutamine solution 1, dicarbonate solution 6 and fetal calf serum 12 through proportionally mixing, adding human embryo skin fibroblast suspension, and external culture.

The present inventors assessed the possibility that bone marrow-derived cells are mobilized to the grafted skin from nonskin tissues and contribute to skin tissue regeneration during the engraftment of grafted skin on biological tissues. As a result, the present inventors for the first time in the world demonstrated that:

(1) a large number of bone marrow-derived cells are mobilized to grafted skin;

(2) mobilized bone marrow-derived cells differentiate into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in grafted skin, and thus mobilized bone marrow-derived cells include bone marrow-derived mesenchymal stem cells;

(3) S100A8 and S100A9 released from necrotic tissues of grafted skin are responsible for mobilizing bone marrow-derived mesenchymal stem cells to the grafted skin from peripheral blood; and

(4) purified S100A8 and S100A9 promote the migration of mesenchymal stem cells isolated/cultured from the bone marrow.